The Psychedelic News Feed
Sept 29 - Oct 5, 2025
This is an archived version of our Psychedelic News Feed. Explore the live Feed and receive a weekly digest to your inbox by joining our free newsletter:
Learn more about and subscribe to our Pα+ program to receive lots, lots more. ∎
A Note from the Editor
If you’re a podcast or radio fan, it’s a great time to be interested in psychedelics. Right now, you can listen to season 2 of the Altered States podcast, catch an episode on the evidence base for psychedelic medicine over at Undark, and enjoy a BBC Radio 4 segment on psychedelics for mental health hosted by Chris and Xand van Tulleken.
If you prefer to consume your media with your eyeballs, psychedelic scientist Manoj Doss and colleagues published a feature on ‘what we know, and what we think we know’ regarding how psychedelics affect the brain in The Scientist. Elsewhere, we published our latest Bulletin, which included our Dispatch from the Borealis Psychedelic Science Summit as well as updates from across the field.
On Wednesday, we unveiled our latest resource: The Psychedelic Perceptions Tracker. We combed through opinion polls, surveys, government reports, and other datasets to produce a curated series of headline figures, charts, and data visualisations on how various groups perceive and interact with psychedelics.
This coming week, we again have something new to share: The Psychedelic Practitioner, a publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and psychedelic-based treatments. Keep an eye out in your inbox for that first Issue next week.
Anyhow, without further ado: Here’s your Psychedelic News Feed, a one-stop digest for the latest coverage of psychedelics business, policy, research and beyond.
Josh Hardman
Founder & Editor
Psychedelic Bulletin #210 (Oct 3) ↗ Psychedelic Alpha
- Dispatch: Borealis Summit Puts Compass’ Minimal Support Model Under Microscope
- IV Ketamine Outperforms IN Esketamine in Retrospective Study
- Reunion Advances RE104 While Academic Preclinical Study of Psilocybin Raises Postpartum Questions
- Mindstate Completes Phase I Study, Teases First Fixed-Dose Combination Program
- New York Assembly Discusses Psilocybin
- Neurocentrx Secures $5M+ From Wellcome to Advance Abuse-Deterrent Ketamine Capsules and Digital Tool Combo
- and more…
The Psychedelics Perceptions Tracker: Our Latest Resource (Oct 1) ↗ Psychedelic Alpha
Why we need basic science to better understand the neurobiology of psychedelics (Oct 1) ↗ The Transmitter
How Psychedelics Affect the Brain: What We Know, and What We Think We Know (Sep 29) ↗ The Scientist
TUNE IN: PODCASTS & RADIO SEGMENTS
Can psychedelics improve your mental health? (Sept 30) ↗ BBC Radio 4
Season 2 of Altered States ↗ PRX
Do We Know Enough to Use Psychedelics As Medicine? (Oct 1) ↗ Undark
One Mind Accelerator Applications Now Open ↗ One Mind
Why abandoning psychedelic research in the 1970s was a blow to science (Oct 1) ↗ New Scientist
Potential legalization of psilocybin, an ingredient in “magic mushrooms,” the subject of NYS Assembly hearing (Sept 30) ↗ CBS News
This is an archived version of our Psychedelic News Feed. Explore the live Feed and receive a weekly digest to your inbox by joining our free newsletter:
Learn more about and subscribe to our Pα+ program to receive lots, lots more. ∎